The University of Montana has received $3.3 million contracts from the National Institutes of Health (NIH) to develop an innovative vaccine targeting opioid addiction.
The Principal Investigator on the two-year award will be Dr. Jay Evans, director of UM’s Center for Translational Medicine and a research professor in the Division of Biological Sciences. Other investigators on the award are Drs. David Burkhart, Kendal Ryter and Helene Bazin-Lee from UM in Missoula, Marco Pravetoni from the University of Minnesota, and Paul Pentel and Mark LeSage from Hennepin Healthcare Research Institute.
Last fall, the National Institute of Allergy and Infectious Diseases and National Institute on Drug Abuse organized a meeting to bring drug abuse and vaccine research teams together with a goal of finding solutions to the growing opioid-use epidemic. As a result, UM partnered with the University of Minnesota and Hennepin Healthcare Research Institute to take on this new challenge. That partnership has now generated new research funds and a promising new vaccine candidate.
“While we’ve made meaningful progress in Montana to prevent opioid abuse from occurring and to decrease overdoses, this invisible epidemic still steals away too many lives in our state and across the nation,” Bullock said. “The potential for a vaccine to treat opioid addiction offers hope in addressing this crisis, and I praise the University of Montana for conducting this important research.”
Opioid-use disorders are associated with heroin and prescription opioids, as well as synthetic opioids such as fentanyl. As an alternative to current small-molecule-based pharmacotherapies targeting opioid receptors – such as methadone or naltrexone – vaccines offer a promising safe and cost-effective strategy to treat opioid use disorders and reduce the risk of overdoses.
“The idea of using vaccines to treat opioid addiction seems strange to most people, but preclinical and clinical evidence suggests this approach can work,” Evans said. “Antibodies generated by the vaccine bind fentanyl and prevent it from crossing the blood-brain barrier. The vaccine itself has no drug-like effects because of the fentanyl hapten – the part the drug recognized by the immune system – is linked to a carrier protein.”
UM scientists at the Center for Translational Medicine have worked on vaccines, adjuvants (compounds that stimulate an immune response) and delivery systems for over 20 years.
Established in 2017, the UM Center for Translational Medicine is a multidisciplinary research center that assists faculty, staff, and students in the translation of preclinical research discoveries from bench to bedside. The center works across the Montana University System to facilitate the ability of researchers to better advance the clinical and commercial potential of their basic science discoveries.
Dr. Jay Evans, director of the University of Montana Center for Translational MedicineSource: